PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.71 USD | 0.00% |
|
+32.84% | +52.25% |
| 03-25 | ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | CI |
| 03-22 | ProKidney Posts Wider 2023 Loss | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 136M 10.85B |
|---|---|---|---|---|---|
| Net income 2024 * | -176M -14.09B | Net income 2025 * | -40M -3.2B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 152M 12.2B | Net cash position 2025 * | 295M 23.62B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-5.44
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 week | +32.84% | ||
| Current month | +65.24% | ||
| 1 month | +72.61% | ||
| 3 months | +90.85% | ||
| 6 months | +80.07% | ||
| Current year | +52.25% |
1 week
2.01
3.02
1 month
1.413.37
Current year
1.183.37
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 16/07/23 |
James Coulston
DFI | Director of Finance/CFO | 48 | 31/12/21 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 30/09/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 31/12/21 |
Brian Pereira
BRD | Director/Board Member | 65 | 31/12/21 |
John Maraganore
BRD | Director/Board Member | 60 | 10/08/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.12 | -21.77% | 1,533,641 |
| 25/04/24 | 2.71 | 0.00% | 495,834 |
| 24/04/24 | 2.71 | +7.11% | 541,639 |
| 23/04/24 | 2.53 | -6.99% | 1,152,575 |
| 22/04/24 | 2.72 | +33.33% | 2,804,606 |
End-of-day quote Nasdaq, April 24, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.12
USD
Average target price
4.2
USD
Spread / Average Target
+98.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.25% | 136M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PROK Stock
